The advent of the IHC technique makes it possible to identify the neuroendocrine phenotypes in breast cancer subpopulations by displaying their immunoreactivity to CgA, Syn, neuron-specific enolase (NSE), and CD56, which are usually negative in IBC-NSTs. This evidence concerns the gene ENO2 and breast carcinoma.